Acute Exercise Effects on Mild Cognitive Impairment
Acute Effects of Exercise, With and Without Anti-Amyloid Therapy, on Fluid Biomarkers in Patients with Mild Cognitive Impairment
Purpose
The purpose of this study is to test how one session of aerobic exercise affects blood components associated with brain health in people with mild cognitive impairment (MCI). We will study this in people who are currently receiving donanemab or lecanemab and those who are not receiving donanemab or lecanemab. The goal is to see if exercise can improve the effects of donanemab or lecanemab. This study will help scientists understand how exercise may support or improve current treatments for people at risk of Alzheimer’s Disease.
Who can Participate
To participate in this study patient must meet the criteria listed below.
Inclusion Criteria:
- Aged 60-90 years
- Diagnosis of MCI or mild dementia, or a MoCA score of 18-25
- Amyloid positive
- Have been receiving anti-amyloid therapy for at least 6 months (group 1) or have never received anti-amyloid therapy (group 2)
- Ability to walk without a walker, cane, or other assistive device
Exclusion Criteria:
- Moderate or severe dementia
- Traumatic brain injury
- Presence of a clinically significant or uncontrolled medical condition for which exercise testing is contraindicated
- Current tobacco use
Visits
If you agree to join this study, your participation will last 1-2 weeks. There will be 1 screening visit at Barrow to determine whether you are eligible. The screening visit will last approximately 1-1.5 hours. If you are eligible, there will be 3 study visits at Arizona State University. Study visit 1 will last 2-3 hours. Study visits 2 and 3 will be about 15 minutes each. Study visits will be scheduled on 3 consecutive days.
